AbCellera Biologics (ABCL) Income Statement: Revenue & Earnings

AbCellera Biologics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

AbCellera Biologics Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	28.83	38.03	489.47	375.20	233.16
Cost of Revenue	167.26	175.66	174.32	45.52	56.54
Gross Profit	28.83	38.03	489.47	329.69	176.62
Operating Expenses
Research & Development	167.26	175.66	107.88	62.06	29.39
Selling, General & Administrative	85.49	250.84	241.07	48.76	15.75
Operating Expenses	329.98	261.08	268.91	107.79	20.59
Operating Income	-301.15	-230.43	220.56	221.90	156.03
Other Income/Expense
Interest Income	38.47	42.25	16.08	3.33	0.29
Interest Expense	0.00	0.00	4.05	5.23	-6.81
Other Income/Expense	62.28	6.78	-10.55	-0.86	8.32
Income
Income Before Tax	-200.40	-174.03	247.19	219.15	157.83
Income Tax Expense	-37.54	-27.63	-80.58	65.69	38.92
Net Income	-162.86	-146.40	327.77	153.46	118.92
Net Income - Continuous Operations	-162.86	-146.40	158.52	153.46	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-204.15	-143.14	280.29	241.62	160.87
EBIT	-301.15	-174.03	247.19	224.37	156.03
Depreciation & Amortization	90.85	24.40	27.84	14.45	4.84
Earnings Per Share
Basic EPS	-1.00	-1.00	1.00	1.00	1.00
Diluted EPS	-1.00	-1.00	1.00	-	-
Basic Shares Outstanding	294.33	289.17	285.06	275.76	159.20
Diluted Shares Outstanding	294.33	289.17	314.83	318.29	263.13